1. Home
  2. EDSA vs MDRR Comparison

EDSA vs MDRR Comparison

Compare EDSA & MDRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDSA
  • MDRR
  • Stock Information
  • Founded
  • EDSA 2015
  • MDRR 2015
  • Country
  • EDSA Canada
  • MDRR United States
  • Employees
  • EDSA N/A
  • MDRR N/A
  • Industry
  • EDSA Biotechnology: Pharmaceutical Preparations
  • MDRR Real Estate Investment Trusts
  • Sector
  • EDSA Health Care
  • MDRR Real Estate
  • Exchange
  • EDSA Nasdaq
  • MDRR Nasdaq
  • Market Cap
  • EDSA 13.8M
  • MDRR 15.6M
  • IPO Year
  • EDSA N/A
  • MDRR 2018
  • Fundamental
  • Price
  • EDSA $2.09
  • MDRR $11.22
  • Analyst Decision
  • EDSA Strong Buy
  • MDRR
  • Analyst Count
  • EDSA 2
  • MDRR 0
  • Target Price
  • EDSA $13.00
  • MDRR N/A
  • AVG Volume (30 Days)
  • EDSA 13.1K
  • MDRR 1.9K
  • Earning Date
  • EDSA 08-08-2025
  • MDRR 08-08-2025
  • Dividend Yield
  • EDSA N/A
  • MDRR 2.40%
  • EPS Growth
  • EDSA N/A
  • MDRR N/A
  • EPS
  • EDSA N/A
  • MDRR N/A
  • Revenue
  • EDSA N/A
  • MDRR $9,485,128.00
  • Revenue This Year
  • EDSA N/A
  • MDRR N/A
  • Revenue Next Year
  • EDSA N/A
  • MDRR N/A
  • P/E Ratio
  • EDSA N/A
  • MDRR N/A
  • Revenue Growth
  • EDSA N/A
  • MDRR N/A
  • 52 Week Low
  • EDSA $1.55
  • MDRR $9.55
  • 52 Week High
  • EDSA $5.59
  • MDRR $15.00
  • Technical
  • Relative Strength Index (RSI)
  • EDSA 55.09
  • MDRR 52.10
  • Support Level
  • EDSA $2.03
  • MDRR $10.09
  • Resistance Level
  • EDSA $2.11
  • MDRR $11.43
  • Average True Range (ATR)
  • EDSA 0.10
  • MDRR 0.45
  • MACD
  • EDSA 0.01
  • MDRR 0.00
  • Stochastic Oscillator
  • EDSA 73.33
  • MDRR 85.57

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

About MDRR Medalist Diversified REIT Inc.

Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.

Share on Social Networks: